Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Revance Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Revance Therapeutics, Inc.’s stock price such as:

• Revance Therapeutics, Inc.’s current stock price and volume
• Why Revance Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for RVNC from analysts
• RVNC’s stock price momentum as measured by its relative strength

About Revance Therapeutics, Inc. (RVNC)

Before we jump into Revance Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Want to learn more about Revance Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Revance Therapeutics, Inc..

Revance Therapeutics, Inc.’s Stock Price as of Market Close

As of January 17, 2025, 4:00 PM, CST, Revance Therapeutics, Inc.’s stock price was $3.680.

Revance Therapeutics, Inc. is up 12.54% from its previous closing price of $3.270.

During the last market session, Revance Therapeutics, Inc.’s stock traded between $3.600 and $3.700. Currently, there are approximately 104.21 million shares outstanding for Revance Therapeutics, Inc..

Revance Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Revance Therapeutics, Inc. Stock Price History

Revance Therapeutics, Inc.’s (RVNC) price is currently up 21.05% so far this month.

During the month of January, Revance Therapeutics, Inc.’s stock price has reached a high of $3.700 and a low of $3.030.

Over the last year, Revance Therapeutics, Inc. has hit prices as high as $7.560 and as low as $2.300. Year to date, Revance Therapeutics, Inc.’s stock is up 21.05%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Revance Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of January 16, 2025,, no analysts have changed their rating of Revance Therapeutics, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Revance Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Revance Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Revance Therapeutics, Inc. (RVNC) by visiting AAII Stock Evaluator.

Relative Price Strength of Revance Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 16, 2025, Revance Therapeutics, Inc. has a weighted four-quarter relative price strength of -18.90%, which translates to a Momentum Score of 12 and is considered to be Very Weak.

Want to learn more about how Revance Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Revance Therapeutics, Inc. Stock Price: Bottom Line

As of January 17, 2025, Revance Therapeutics, Inc.’s stock price is $3.680, which is up 12.54% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Revance Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.